As I tweeted already, a new journal devoted to nucleic acid-based therapeutics, Molecular Therapy-Nucleic Acids (MTNA), just came online. The first articles already indicate that this journal is poised to become an important addition to the field of RNAi Therapeutics: promising siRNA chemistry work by Merck, folate-siRNA conjugates by Roche, and an article on SNALP and 'lipidoid' delivery to immune cells by Alnylam. Today, a review by myself on 'The Business of RNAi Therapeutics in 2012' analyzes the dramatic ups and downs this field has experienced in its less than 10 years in existence, with a particular focus on the downturn following the 2007/2008 peak. I believe that it is timely in that the industry is entering a new, recovery phase. 
Showing posts with label The Business of RNAi Therapeutics. Show all posts
Showing posts with label The Business of RNAi Therapeutics. Show all posts
Tuesday, February 7, 2012
The Business of RNAi Therapeutics in 2012
As I tweeted already, a new journal devoted to nucleic acid-based therapeutics, Molecular Therapy-Nucleic Acids (MTNA), just came online. The first articles already indicate that this journal is poised to become an important addition to the field of RNAi Therapeutics: promising siRNA chemistry work by Merck, folate-siRNA conjugates by Roche, and an article on SNALP and 'lipidoid' delivery to immune cells by Alnylam. Today, a review by myself on 'The Business of RNAi Therapeutics in 2012' analyzes the dramatic ups and downs this field has experienced in its less than 10 years in existence, with a particular focus on the downturn following the 2007/2008 peak. I believe that it is timely in that the industry is entering a new, recovery phase. 
Friday, April 25, 2008
The Business of RNAi Therapeutics
I’m often asked about explaining RNAi and its potential as a therapeutic modality and investment in more layman terms. I hope my review, The Business of RNAi Therapeutics, that came out today in Human Gene Therapy will be able to address at least some of these questions. Although originally written with the scientist in mind asking him/herself about what the development of RNAi Therapeutics may mean as an investment or business opportunity, the science should be pretty digestible and accessible to the scientifically minded lay public. Here’s the abstract, the rest is freely accessible on the Human Gene Therapy website:
Business for RNAi Therapeutics has never been better. The confluence of the genome revolution, a pharmaceutical industry greatly challenged by generic competition and starved for innovation, and pre-existing nucleic acid drug development know-how that can now be directly applied to RNAi Therapeutics, means that RNAi, less than 10 years after its discovery in worms, has every chance of becoming the next major drug development platform for improving healthcare and generating profits at multiple levels. From the perspective of a molecular biologist interested in both basic and applied aspects of RNAi and related investments, I would like to first put RNAi into the context of the drug development enterprise and then discuss various strategies for translating the science of RNAi into commercially viable drugs as well as some of the risks the industry faces. While the discussion will focus on RNAi Therapeutics and the major US and European markets, it should be kept in mind that RNAi is a global effort and holds further commercial promise in agriculture, the research reagent and services markets, and the related area of microRNA-based therapeutics and diagnostics. Read on…here
Business for RNAi Therapeutics has never been better. The confluence of the genome revolution, a pharmaceutical industry greatly challenged by generic competition and starved for innovation, and pre-existing nucleic acid drug development know-how that can now be directly applied to RNAi Therapeutics, means that RNAi, less than 10 years after its discovery in worms, has every chance of becoming the next major drug development platform for improving healthcare and generating profits at multiple levels. From the perspective of a molecular biologist interested in both basic and applied aspects of RNAi and related investments, I would like to first put RNAi into the context of the drug development enterprise and then discuss various strategies for translating the science of RNAi into commercially viable drugs as well as some of the risks the industry faces. While the discussion will focus on RNAi Therapeutics and the major US and European markets, it should be kept in mind that RNAi is a global effort and holds further commercial promise in agriculture, the research reagent and services markets, and the related area of microRNA-based therapeutics and diagnostics. Read on…here
Subscribe to:
Posts (Atom)